Derived from Atea’s nucleos(t)ide platform, bemnifosbuvir (AT-527) is an oral direct acting antiviral being evaluated in the global Phase 3 SUNRISE-3 registrational trial for the treatment of COVID-19. Bemnifosbuvir targets the SARS-CoV-2 RNA polymerase (nsp12), a highly conserved gene that is unlikely to change as the virus mutates and new variants continue to emerge. This gene is responsible for both replication and transcription of SARS-CoV-2. Bemnifosbuvir has a unique mechanism of action, with dual targets consisting of chain termination (RdRp) and nucleotityltransferase (NiRAN) inhibition, which has the potential to create a high barrier to resistance.
Atea is a clinical stage biopharmaceutical company working to address unmet medical needs with innovative oral antiviral therapies.
Leveraging our platform, we have discovered and are rapidly advancing novel oral direct-acting antiviral drug candidates. Utilizing unique chemical modifications, these product candidates are designed to have the potential for enhanced antiviral activity and selectivity.
For the treatment of COVID-19, we need transformational solutions, and we believe that oral, safe, direct-acting antivirals can play an essential role worldwide. The value and global health impact of a direct-acting antiviral is to rapidly inhibit viral replication in the early phase of infection, which has the effect of reducing disease progression and curtailing the spread of infection.
While vaccines will play an important role in mitigating the COVID-19 pandemic, we will need treatment options to stay ahead of the virus.
Complementary medical intervention to vaccination
Oral administration has significant advantages:
Highly-conserved target has potential to enable antiviral activity in the presence of multiple variants
Antiviral activity against potential future coronaviruses beyond SARS-CoV-2 anticipated
See updates on bemnifosbuvir, other Atea product candidates and company news.
Enrollment Progresses in SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 with Interim Analysis Expected 2H23 Proof-of-Concept Results for AT-752 for Dengue Expected 1Q23 Enrollment Expected to Initiate 2Q23 for Phase 2 Combination
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will present a business update at the 41 st
Global Study to Evaluate Bemnifosbuvir as Monotherapy and in Combination in Non-Hospitalized Patients at High Risk of Disease Progression, Regardless of Vaccination Status Phase 3 Evaluation of Bemnifosbuvir Supported by Clinical Data from Late-Stage MORNINGSKY Trial and Prior Studies
Atea is a clinical-stage biopharmaceutical company working to address unmet medical needs through novel antiviral treatments.
Copyright © 2020 By Atea Pharmaceuticals. All Rights Reserved. Privacy Policy | Terms of Use